ClinicalTrials.gg
RecruitingNCT05163899OCCULTUpdated May 14, 2026

Investigation of Surgical Sectioning of the Filum Terminale in Treating Occult Tethered Cord Syndrome Patients

An interventional study of Release of filum terminale in Tethered Cord, Tethered Cord Syndrome and Occult Spina Bifida, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 2 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
2 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 968 studies in Spinal Cord Injuries with a site in United States — 249 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Planned enrollment
444th of 836
20 · median 24
Started
2022
with 64 others
No phase
601 of 968
189 open now
Primary completion
2027-12
later than 200 of 307 live
Registered
667th of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 444th largest by planned enrollment of the 836 interventional ones that give a count, is one of 65 that started in 2022, is one of 601 with no phase, reaches primary completion later than 200 of the 307 other live ones, and was the 667th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

249 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

244 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 2 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

The investigators hypothesize that surgical release of the filum terminale (strand of fibrous tissue at the end of the spinal cord) is a more efficacious treatment option for symptomatic relief than medical management in subjects with Occult Tethered Cord Syndrome (OTCS) and that the risks do not outweigh the benefit profile.

Read the detailed description

This is a phase II pilot randomized-controlled, single-site trial to determine if surgical untethering of the filum terminale is more effective, preliminarily, than medical management as a treatment option for OTCS. Subjects will be randomized to one of two arms: surgical untethering or medical management only. Symptom improvement and adverse events will be assessed and recorded for 1 year from initiation of treatment. After a minimum of 1 year, subjects who were randomized to the medical management arm may cross over to the surgical arm if the PI deems it is in the subject's best interest to do so. The exploratory hypothesis is that surgery for OTCS is both safe and more effective than medical management at relieving the symptoms of OTCS.

03

Conditions studied

  • Tethered Cord
  • Tethered Cord Syndrome
  • Occult Spina Bifida
  • Spina Bifida Occulta

Keywords

  • tethered cord
  • occult
  • filum terminale
  • tight filum
04

Who can participate

Ages eligible
2 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 2 and \< 80 years of age.
  • to medical management of symptoms for at least 1 year.
  • Documentation of OTCS, as defined by a total score of at least 30 on the following scale:

OCCULT Grading Scale (Score 0-100) Orthopedic Abnormality: 0-15; Central Nervous System Dysfunction: 0-25; Cutaneous Stigmata: 0-10; Urological or Bowel Dysfunction: 0-25; Lumbosacral Anatomy: 0-15; Tissue Integrity Disorder: 0-10.

Exclusion criteria

Exclusion Criteria:

  • Subjects \< 2 or > 80 years of age.
  • Radiographically identified tethered cord, as defined by any of the following:

    • A low-lying conus (at or below the L2-3 disc space)
    • A thickened filum (>2 mm)
    • Fat in the filum or lipoma
    • Distinct adhesion or tethering.
  • A history of Meningocele manqué or Myelomeningocele.
  • Cutaneous markings of dermal sinus tract.
  • History of prior surgery on the lumbar spine.
  • History of prior surgery for spinal dysraphism.
  • History of prior infection or condition of the central nervous system.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Surgery

    Filum release

    Procedure: Release of filum terminale

  • No intervention
    Observation

    Medical Management only

Interventions

  • ProcedureRelease of filum terminale

    Surgery will be offered to section the filum terminale

    Also known as: Laminectomy for tethered cord release

06

What researchers measure

Primary outcomes

  1. Change in symptoms related to tethered cord, as measured by the OCCULT Scale

    Combination of neurologic, urologic, orthopedic, and cutaneous assessments. The OCCULT Scale is from 0-100, with 0 being none of the listed signs/symptoms present and 100 being all listed signs/symptoms present with maximum severity.

    Time frame: Baseline, 1 year

Secondary outcomes

  1. Change in urologic incontinence score

    Score is measured by the International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form. The minimum score is 0 and the maximum score is 21. The higher the score, the more severe the urinary incontinence symptoms and/or effect of symptoms on quality of life.

    Time frame: Baseline, 1 year

  2. Change in fecal incontinence score

    Score is measured by the Rapid Assessment Faecal Incontinence Score. The minimum score is 0 and the maximum score is 20. The higher the score, the more severe the fecal incontinence symptoms and/or effect of symptoms on quality of life.

    Time frame: Baseline, 1 year

  3. Number of patients who cross over

    Time frame: 1 year

  4. Percent of patients with a decrease in anticholinergic medications at 1 year post-surgery

    For patients who presented with urological symptoms

    Time frame: 1 year

  5. Number of intra-operative findings that are discordant with MRI interpretations

    To examine whether there is a limitation in MRI in identifying pathology that is identified at the time of surgery

    Time frame: Intraoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Michael MM, Garton ALA, Kuzan-Fischer CM, Uribe-Cardenas R, Greenfield JP. A critical analysis of surgery for occult tethered cord syndrome. Childs Nerv Syst. 2021 Oct;37(10):3003-3011. doi: 10.1007/s00381-021-05287-5. Epub 2021 Jul 15. PubMed 34268593 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2027, 67 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 67 months is above that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Dec 20, 2021
StartActual
May 19, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05163899
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
May 19, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 14, 2026

Study contacts

Cynthia Nguyen
Contact
cyn4002@med.cornell.edu
(212) 746-1788
Jeffrey Greenfield, MD, PhD
Contact
jpgreenf@med.cornell.edu
(212) 746-2363
Jeffrey Greenfield, MD, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion